Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India
- 65 Downloads
Autologous stem cell transplantation (ASCT) is considered as standard of care in patients with multiple myeloma (MM) patients aged 65 years or younger. We analyzed data of 94 patients of plasma cell dyscrasias who underwent 95 autologous transplants at our institute from October 2003 to Aug 2016. Other than 76 patients of newly diagnosed multiple myeloma, we also transplanted two patients of POEMS syndrome, two patients of plasma cell leukemia, three patients of concurrent light chain deposition disease, three patients of multifocal plasmacytomas, and eight patients of isolated light chain myeloma. One patient underwent transplant twice. The median age of patients was 53 years (range 21–65). The average interval between diagnosis and transplant was 10.51 ± 5.42 months. The predominant stage in the study cohort was ISS-III. IgG kappa was the commonest subtype of plasma cell dyscrasia (27.9%) followed by IgG lambda (16.27%). Renal involvement was seen in 25% patients at the time of transplantation. Following chemotherapy, 42% patients were in CR, 39% in VGPR, 5% had PR and 14% had progressive disease at the time of transplantation. All patients were conditioned with melphalan (dose 120–200 mg/m2) except for one who received an additional bortezomib for his second transplant. The mean time to neutrophil and platelet engraftment was 11.09 ± 1.82 and 12.69 ± 4.55 days respectively. Mucositis was noted in all patients (grade 3 in 37.5% patients). The median PFS (biochemical) was 55.8% and PFS (clinical) was 76.7% at 6.5 years. Thirteen percent of the transplanted patients succumbed to their illness of which three patients died within 30 days of transplant. Median OS was 76.7% at 6.5 years. ASCT is a feasible option for MM in India and the results are comparable.
keywordsASCT Myeloma Real World Transplant Autologous
Compliance with Ethical Standards
Conflict of interest
All Authors declare that they have no conflict of interest.
Human and Animal Rights
This research is involving human participants.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Kumar L, Verma R, Radhakrishnan VR (2010) Recent advances in the management of multiple myeloma. Nat Med J India 23(4):210–218Google Scholar
- 8.Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC et al (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transpl 13(2):183–196CrossRefGoogle Scholar
- 12.Nath UK, Chakrabarti P, Ray SS, Chaudhuri U (2010) Starting autologous transplantation in a non-hepa filtered unit in a medical college with severe resource constraints. Indian J Hematol Blood Transfus 26(4):172Google Scholar
- 14.Ashok P, Mani K, Sadashivudu G, Srinivas ML (2015) Study of quality of life in multiple myeloma patients after autologous stem cell transplantation. Indian J Hematol Blood Transf 1:S67–S68Google Scholar
- 16.Gupta A, Kumar L, Dabkara D, Gupta D, Sharma O, Sreeniwas V (2009) Multiple myeloma: autologous stem cell transplantation versus conventional chemotherapy—a retrospective age and stage matched analysis. J Clin Oncol 1:7041Google Scholar
- 17.Lu J, Hou J, Liu K-Y, Parmar S, De La Fuente A, Andersson B et al (2016) Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th international hematologic malignancies conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma 57(7):1534–1538CrossRefPubMedGoogle Scholar
- 18.Prakash Yadav S, Kalra M, Sachdeva A, Dinand V, Parashar N, Kohli S et al (2009) The experience of hematopoietic stem cell transplantation from an emerging centre in north India. In: Blood conference: 51st annual meeting of the American society of hematology, ASH New Orleans, LA United States Conference Start, vol 114, no. 22Google Scholar
- 19.Sagar TG, Rathinam K, Trivadi G, Rejiv R, Prasanth G (2015) Outcomes in multiple myeloma post high dose chemotherapy and autologous stem cell transplantation-single institute experience. Indian J Hematol Blood Transf 1:S65Google Scholar
- 21.Kumar L (2013) Autologous stem cell transplant for multiple myeloma. Indian J Hematol Blood Transf 29(4):243Google Scholar
- 22.Dolai TK, Kumar M, Kumar Mandal P, Saha S, Bagchi B, Panigrahi A et al (2013) Auto-SCT for myeloma patients in non-HEPA filtered room: initial experience of a tertiary care center. Leuk Lymphoma 54:26Google Scholar
- 26.Bagal B, Jain H, Dangi U, Sengar M, Kannan S, Rangarajan V et al (2014) Pretransplant PET positivity predicts early relapse with poor outcome in patients of multiple myeloma undergoing autologous stem cell transplantation. Blood 124(21):3997Google Scholar
- 28.Aggarwal S, Bhalla A, Khatri SL, Anand Simar S, Bhargava M, Saran R (2011) Bortezomib plus dexamethasone as induction treatment followed by autologous peripheral blood stem cell transplantation in patients with multiple myeloma: a study from india. In: Blood conference: 53rd annual meeting of the American society of hematology, ASH, vol 118, no. 21Google Scholar
- 29.Bagal BP, Khattry N, Dongre A, Kanan S, Menon H, Sengar M et al (2012) Outcomes of autologous stem cell transplant (ASCT) in multiple myeloma from a tertiary cancer center in India. J Clin Oncol Conf 30(15 SUPPL. 1):e17003Google Scholar
- 32.Reddy R, Bakhshi S, Sharma A, Sahoo R, Gogia A, Malik PS et al (2015) Poor mobilization of peipheral blood stem cells (PBSC) in patients undergoing autologous stem cell transplantation (ASCT): a prospective study. J Clin Oncol Conf 33(15 SUPPL. 1):e18013Google Scholar